Prelude Therapeutics Incorporated
Last updated September 27, 2026
Organization details
- Legal name
- Prelude Therapeutics Incorporated
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- PRLD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001678660
Board of directors
-
David P. Bonita · DirectorSince 2023
- Since 2023
- Since 2023
-
Katina Dorton · DirectorSince 2025
-
Krishna Vaddi · Director · CEOSince 2023
-
Mardi Dier · DirectorSince 2023
-
Martin Babler · DirectorSince 2023
-
Paul A. Friedman · DirectorSince 2023
-
Paul C. Scherer · DirectorSince 2025
-
Victor Sandor · DirectorSince 2023
Chief executives
Krishna Vaddi
· CEO
Dates unknown
Board connections
8 of this board's directors also sit on 22 other boards.
- via Felix Baker, Julian Baker and Victor Sandor
- via Felix Baker, Julian Baker and Paul A. Friedman
- via Felix Baker, Julian Baker and Martin Babler
- via Felix Baker, Julian Baker and Katina Dorton
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Felix Baker and Julian Baker
- via Victor Sandor
- via Victor Sandor
- via Martin Babler
- via Katina Dorton
- via David P. Bonita
- via Martin Babler
- via Mardi Dier
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $24,999,997
- 4 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 27, 2026 | Rajeev M. Shah 10% owner | Other | −1,407,000 | — | — |
| Apr 21, 2026 | David P. Bonita Director, 10% owner | Open-market purchase | +1,689,189 | $4.44 | $7,499,999 |
| Apr 21, 2026 | OrbiMed Genesis GP LLC Director, 10% owner | Open-market purchase | +1,689,189 | $4.44 | $7,499,999 |
| Apr 21, 2026 | David P. Bonita Director, 10% owner | Open-market purchase | +1,126,126 | $4.44 | $4,999,999 |
| Apr 21, 2026 | OrbiMed Genesis GP LLC Director, 10% owner | Open-market purchase | +1,126,126 | $4.44 | $4,999,999 |
| Oct 4, 2025 | Jane Huang Officer (President, CMO) | Option exercise | +9,375 | — | — |
| Oct 4, 2025 | Jane Huang Officer (President, CMO) | Shares withheld for tax | −3,355 | $1.47 | $4,932 |
| Jul 4, 2025 | Jane Huang Officer (President, CMO) | Option exercise | +9,375 | — | — |
| Jul 4, 2025 | Jane Huang Officer (President, CMO) | Shares withheld for tax | −3,355 | $0.79 | $2,650 |
| Apr 4, 2025 | Jane Huang Officer (President, CMO) | Option exercise | +9,375 | — | — |
| Apr 4, 2025 | Jane Huang Officer (President, CMO) | Shares withheld for tax | −3,355 | $0.68 | $2,281 |
| Mar 25, 2025 | Combs Andrew Officer (Chief Chemistry Officer) | Open-market purchase | +100,000 | $0.69 | $69,000 |
| Mar 25, 2025 | Krishna Vaddi Director, Officer (CEO) | Open-market purchase | +675,000 | $0.69 | $465,750 |
| Mar 21, 2025 | Krishna Vaddi Director, Officer (CEO) | Open-market purchase | +15,000 | $0.73 | $10,950 |
| Mar 20, 2025 | Krishna Vaddi Director, Officer (CEO) | Open-market purchase | +5,416 | $0.73 | $3,954 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.